ストックスクリーナーアプリを入手
2.07
1.47%
0.03
アフターアワーズ：
2.08
0.01
+0.48%
Inflarx Nv (IFRX) 最新ニュース
Commodore Capital reports 5%+ stake in InflaRx (IFRX) - Stock Titan
InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan
Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan
InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan
EDGAR Filing Documents for 0001140361-26-033149 - SEC.gov
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
InflaRx (IFRX) Short Interest & Short Float | Updated Aug 2026 $IFRX - MarketBeat
HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan
InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView
InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan
IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey
InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan
InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada
IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com
InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView
No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net
IFRX Q2'26 Earnings: revenue estimate is 6.40K USD - TradingView
InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Cash Flow - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
IFRX Stock Price, Quote & Chart - ChartMill
InflaRx N.V. (IFRX) Hovers Near Support After Marginal DeclineMA Cross Alert - dars.gov.et
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock EasesEarnings Call Q&A - DonanımHaber
InflaRx NV focus on immune therapies as investors weigh long-term prospects - ad-hoc-news.de
InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support LevelETF Premium Discount - DonanımHaber
IFRX Q1 2026 Earnings: Surprise EPS Beat Despite Pre-Revenue StatusCapex Guidance - dars.gov.et
Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
IFRXInflaRx NV Revenue Breakdown - Finviz
Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks
InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
InflaRx to explore regulatory path for AAV drugs in Europe - Investing.com
InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com - Investing.com South Africa
InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV - Quiver Quantitative
InflaRx Assessing Feasibility of Broadened Strategy - One News Page
symbol__ Stock Quote Price and Forecast - CNN
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - The Manila Times
Price to sales forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBITDA forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Price to earnings forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to sales forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to book forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBIT forward of InflaRx N.V. – GETTEX:IF0 - TradingView
ETFs Investing in InflaRx N.V. Stocks - TradingView
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):